| Year |
Citation |
Score |
| 2009 |
Lin X, Wang X, Capek HL, Simone LC, Tuli A, Morris CR, Reber AJ, Solheim JC. Effect of invariant chain on major histocompatibility complex class I molecule expression and stability on human breast tumor cell lines. Cancer Immunology, Immunotherapy : Cii. 58: 729-36. PMID 18828016 DOI: 10.1007/S00262-008-0595-1 |
0.599 |
|
| 2007 |
Ashour AE, Lin X, Wang X, Turnquist HR, Burns NM, Tuli A, Sadanandam A, Suleiman K, Singh RK, Talmadge JE, Solheim JC. CCL21 is an effective surgical neoadjuvant for treatment of mammary tumors. Cancer Biology & Therapy. 6: 1206-10. PMID 17617742 DOI: 10.4161/Cbt.6.8.4405 |
0.62 |
|
| 2007 |
Ashour AE, Turnquist HR, Burns N, Wang X, Lin X, Tremayne J, Hollingsworth MA, Blonder JM, Rosenthal GJ, Talmadge JE, Solheim JC. Flt3 ligand delivered in a pluronic formulation prolongs the survival of mice with orthotopic pancreatic adenocarcinoma. Cancer Biotherapy & Radiopharmaceuticals. 22: 235-8. PMID 17600470 DOI: 10.1089/Cbr.2007.336 |
0.685 |
|
| 2007 |
Turnquist HR, Lin X, Ashour AE, Hollingsworth MA, Singh RK, Talmadge JE, Solheim JC. CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity. International Journal of Oncology. 30: 631-9. PMID 17273764 DOI: 10.3892/Ijo.30.3.631 |
0.709 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2014 |
Lin X, Shi X, Zeng W, Zheng M, Huang L. Salvage therapy with mitoxantrone, etoposide, bleomycin and dexamethasone for refractory or relapsed aggressive non-Hodgkin's lymphoma patients with a poor performance status or comorbidity. Oncology Letters. 8: 2012-2016. PMID 25295084 DOI: 10.3892/ol.2014.2517 |
0.161 |
|
| 2010 |
Zhang ZF, Huang Y, Shi X, Wang RX, Lin XY, Lin XD, Zheng H, Li LB. [Inhibitory effect of photodynamic therapy combined with paclitaxel on the proliferation of esophageal carcinoma Eca-109 cells]. Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University. 30: 1310-2, 1315. PMID 20584640 |
0.134 |
|
| 2011 |
Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, ... Lin X, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2904-9. PMID 21690468 DOI: 10.1200/Jco.2010.33.9275 |
0.122 |
|
| 2016 |
Deng Y, Chen X, Ye Y, Shi X, Zhu K, Huang L, Zhang S, Ying M, Lin X. Histological characterisation and prognostic evaluation of 62 gastric neuroendocrine carcinomas. Contemporary Oncology (Poznań, Poland). 20: 311-9. PMID 27688729 DOI: 10.5114/wo.2016.61852 |
0.073 |
|
| 2014 |
Huang LM, Shi X, Yan DF, Zheng M, Deng YJ, Zeng WC, Liu C, Lin XD. Association between ERCC2 polymorphisms and glioma risk: a meta-analysis. Asian Pacific Journal of Cancer Prevention : Apjcp. 15: 4417-22. PMID 24969862 |
0.045 |
|
| 1999 |
Lin X, Choi JH, Lynch P, Xi L, Wu E, Frazier ML. Reduction in hMSH2 mRNA levels by premature translation termination: implications for mutation screening in hereditary nonpolyposis colorectal cancer. Digestive Diseases and Sciences. 44: 553-9. PMID 10080150 DOI: 10.1023/A:1026609524482 |
0.045 |
|
| Hide low-probability matches. |